XXXX : clinical effects and urinary excretion in treatment of female urge @entity322 .

@entity1 @entity322 @entity73219 @entity2133 @entity50514
Eighteen @entity1 (median age 54 years, 36-79) with urinary motor urge (n = 13) or sensory urge (n = 5) @entity322 were treated for three 2-week periods with @entity73219 (EC) ( @entity50514 Novum) in daily doses of 500 and 1000 mg and placebo. Subjectively the @entity1 experienced an increased ability to control micturition, i.e. less urge, during EC treatment. Only mild and mainly anticholinergic side effects were recorded, most frequently @entity2133 . As regards side effects, the evaluation of objective effects were complicated by a tendency towards carry-over effect to placebo. Placebo in the first treatment periods were analysed solely; no effects of placebo could be demonstrated. Compared with the reference period, decreases in the total number of micturitions (approx. 20%) and in the number of urge @entity322 episodes (approx. 75%) were seen. As compared with placebo, a significant increase (approx. 25%) in the average micturition volume could be demonstrated. The percentage urinary excretion of @entity50514 decreased with increasing oral intake and with advancing age. Probably, an initial daily dosage of 500 mg EC will do well in younger @entity1 (less than 50 years), whereas elder @entity1 may need 1000 mg. Further dosage recommendations are given.
